Table 4 Use of cardiovascular drugs in Mexico categorized by cardiovascular disease and in the overall study population
Study population N = 820 | CVD status | Overall study population (n = 9823) | ||
|---|---|---|---|---|
CVD n = 302 | No CVD n = 518 | |||
Antihypertensive drugs and other CVD agents | 63.3% | 84.8% | 50.8% | 61.4% |
Lipid lowering drugs | 48.2% | 49.6% | 47.6% | 54.1% |
Statins | 43.4% | 44.2% | 43.1% | 51.0% |
Ezetimibe | 4.8% | 7.1% | 3.8% | NA |
PCS9 inhibitors | 0.1% | 0 | 0.2% | NA |
Platelet aggregation inhibitors | 30.1% | 63.2% | 10.8% | 33.5% |
Anticoagulants | 3.4% | 7.9% | 0.8% | 4.3% |
Diuretics | 24.8% | 37.4% | 17.4% | 22.4% |